Compare BWEN & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWEN | SKYE |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 44.9M |
| IPO Year | N/A | N/A |
| Metric | BWEN | SKYE |
|---|---|---|
| Price | $3.79 | $1.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $14.75 |
| AVG Volume (30 Days) | 256.7K | ★ 604.7K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $153,877,000.00 | N/A |
| Revenue This Year | $11.68 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.41 | $0.68 |
| 52 Week High | $3.85 | $5.75 |
| Indicator | BWEN | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 68.51 | 50.87 |
| Support Level | $2.79 | $0.68 |
| Resistance Level | $3.85 | $1.15 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 94.34 | 80.67 |
Broadwind Inc is a precision manufacturer of structures, equipment and components for clean technology and other specialized applications. The company provide technologically high value products to customers with complex systems and stringent quality standards that operate in energy, mining and infrastructure sectors, in the United States of America. It capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treat, assembly, engineering and packaging solutions. It operates through four operating segments namely Heavy Fabrications, Gearing, Industrial Solutions and Corporate.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.